| Autor: |
Aaron, Yap, Adeline, Kho, John, Ah-Chan |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
The New Zealand medical journal. 134(1534) |
| ISSN: |
1175-8716 |
| Popis: |
To describe the outcomes of patients with newly diagnosed neovascular age-related macular degeneration (nAMD) treated in Palmerston North over the past two years.A large prospective database was developed to capture the treatment and visual outcomes of patients with newly diagnosed nAMD. Data were subsequently extracted and analysed according to the result-based accountability (RBA) framework.Fifty-three patients in 2018 and 40 patients in 2019 were identified as having newly diagnosed nAMD. On average, there was an improvement in duration between the date of triage and the first intravitreal injection by eight days (22.7 vs 14.3 days), thus meeting national guidelines to assess and treat new referrals within 14 days. The total number of injections for the 2018 cohort was 227 compared to 301 in 2019. The percentage of patients achieving stabilisation of vision (≤15 letters vision loss, 82.5% vs 93.2%) and improvement in vision (≥15 letters gain, 10.5% vs 31.8%) was higher in 2019 compared to 2018. The percentage of patients that retained driving standard (ie, visual acuity of 6/12) was similar across both years (58.3% vs 62.5%).Patients receiving treatment for newly diagnosed nAMD in Palmerston North were achieving high rates of stabilisation and improvements in visual acuity, with more than half maintaining the national driving standard. The locally developed prospective database allows for real-time analysis of patient outcomes and the evaluation of the effectiveness of quality-improvement strategies. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
